

Maria Pia amato

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8772511/maria-pia-amato-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|--------------------|--------------------------|----------------|-----------------|
| 281 papers | 14,775 citations | 67 h-index | 111 g-index |
| 294 ext. papers | 17,228 ext. citations | 5.3 avg, IF | 6.09 L-index |

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 281 | Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9, | 9.1 | 4 |
| 280 | Comparing natural history of early and late onset pediatric multiple sclerosis.. <i>Annals of Neurology</i> , 2022 , | 9.4 | 2 |
| 279 | The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211069068 | 5 | 1 |
| 278 | Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis.. <i>Frontiers in Neurology</i> , 2022 , 13, 787160 | 4.1 | 1 |
| 277 | Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221079598 | 5 | 1 |
| 276 | The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 61, 103757 | 4 | 0 |
| 275 | Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.. <i>Neurology</i> , 2022 , 98, e1626-e1636 | 6.5 | 0 |
| 274 | The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221088190 | 5 | 0 |
| 273 | Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDIatric Italian Genetic and enviRonment ExposurE Questionnaire). <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 20552173211059048 | 2 | |
| 272 | Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study. <i>Neurology</i> , 2021 , | 6.5 | 4 |
| 271 | Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and Prognosis. <i>Brain Sciences</i> , 2021 , 11, | 3.4 | 1 |
| 270 | Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211005339 | 5 | 18 |
| 269 | Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021 , | 6.5 | 8 |
| 268 | Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. <i>JAMA Neurology</i> , 2021 , 78, 414-425 | 17.2 | 23 |
| 267 | PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , 2021 , 1 | 5.5 | 3 |
| 266 | Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211023365 | 5 | 2 |
| 265 | Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211019650 | 5 | 1 |

| | | | |
|-----|---|-----|----|
| 264 | Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021 , 97, e869-e880 | 6.5 | 3 |
| 263 | The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 479-482 | 5 | 2 |
| 262 | Gray matter atrophy cannot be fully explained by white matter damage in patients with MS. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 39-51 | 5 | 9 |
| 261 | Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 430-438 | 5 | 1 |
| 260 | Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. <i>European Journal of Neurology</i> , 2021 , 28, 1299-1307 | 6 | 1 |
| 259 | The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. <i>Journal of Clinical Psychology in Medical Settings</i> , 2021 , 28, 149-160 | 6.6 | 9 |
| 258 | Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211019574 | 6.6 | 9 |
| 257 | Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. <i>Neurotherapeutics</i> , 2021 , 18, 905-919 | 6.4 | 6 |
| 256 | Early Predictors of 9-Year Disability in Pediatric Multiple Sclerosis. <i>Annals of Neurology</i> , 2021 , 89, 1011-1022 | 6.4 | 3 |
| 255 | Cognitive Issues in Pediatric Multiple Sclerosis. <i>Brain Sciences</i> , 2021 , 11, | 3.4 | 1 |
| 254 | The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Can Protect Against Cognitive Impairment in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021 , 12, 645220 | 4.1 | 3 |
| 253 | Current international trends in the treatment of multiple sclerosis in children-Impact of the COVID-19 pandemic. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 56, 103277 | 4 | 2 |
| 252 | Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211048397 | 5 | 1 |
| 251 | Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis. <i>Neurological Sciences</i> , 2020 , 41, 3185-3193 | 3.5 | 6 |
| 250 | Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520924595 | 5 | 6 |
| 249 | Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520925369 | 5 | 14 |
| 248 | Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event. <i>Annals of Neurology</i> , 2020 , 88, 407-417 | 9.4 | 35 |
| 247 | Disease-modifying therapy aids cognition in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2020 , 16, 525-536 | 5.3 | 3 |

| | | | |
|-----|--|------|----|
| 246 | Study protocol: improving cognition in people with progressive multiple sclerosis: a multi-arm, randomized, blinded, sham-controlled trial of cognitive rehabilitation and aerobic exercise (COGEx). <i>BMC Neurology</i> , 2020 , 20, 204 | 3.1 | 14 |
| 245 | A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon- β in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 40, 101952 | 4 | |
| 244 | Tracking cognitive impairment in multiple sclerosis using the Brain on Track test: a validation study. <i>Neurological Sciences</i> , 2020 , 41, 183-191 | 3.5 | 2 |
| 243 | The caring experience in multiple sclerosis: Caregiving tasks, coping strategies and psychological well-being. <i>Health and Social Care in the Community</i> , 2020 , 28, 236-246 | 2.6 | 9 |
| 242 | Sex effects across the lifespan in women with multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420936166 | 6.6 | 19 |
| 241 | Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020 , 143, 2742-2756 | 11.2 | 8 |
| 240 | Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. <i>Lancet Neurology</i> , <i>The</i> , 2020 , 19, 860-871 | 24.1 | 83 |
| 239 | Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. <i>Brain</i> , 2020 , 143, 3013-3024 | 11.2 | 20 |
| 238 | Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. <i>Disability and Rehabilitation</i> , 2020 , 42, 3780-3792 ^{2.4} | | 12 |
| 237 | Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. <i>Journal of Neurology</i> , 2019 , 266, 3098-3107 | 5.5 | 1 |
| 236 | Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , <i>The</i> , 2019 , 18, 185-197 | 24.1 | 74 |
| 235 | Aging with multiple sclerosis: prevalence and profile of cognitive impairment. <i>Neurological Sciences</i> , 2019 , 40, 1651-1657 | 3.5 | 24 |
| 234 | Identifying risk factors for cognitive issues in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2019 , 19, 333-347 | 4.3 | 17 |
| 233 | Breastfeeding and post-partum relapses in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1211-1216 | 5 | 15 |
| 232 | Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors. <i>PLoS ONE</i> , 2019 , 14, e0222929 | 3.7 | 11 |
| 231 | The Italian multiple sclerosis register. <i>Neurological Sciences</i> , 2019 , 40, 155-165 | 3.5 | 42 |
| 230 | Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 399-407 | 5 | 20 |
| 229 | Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 214-221 | 5 | 43 |

| | | | |
|-----|--|-----|-----|
| 228 | Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. <i>Neurology</i> , 2018 , 90, e823-e831 | 6.5 | 54 |
| 227 | Multiple sclerosis in 2017: Progress in multiple sclerosis - from diagnosis to therapy. <i>Nature Reviews Neurology</i> , 2018 , 14, 72-74 | 15 | 5 |
| 226 | "Brain reserve" and "cognitive reserve" should always be taken into account when studying neurodegeneration - Commentary. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 577-578 | 5 | 1 |
| 225 | Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. <i>Neurology</i> , 2018 , 90, e832-e839 | 6.5 | 48 |
| 224 | ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , 2018 , 25, 215-237 | 6 | 96 |
| 223 | ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 96-120 | 5 | 286 |
| 222 | Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 590-603 | 5 | 58 |
| 221 | Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 642-652 | 5 | 18 |
| 220 | Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1234-1242 | 5 | 24 |
| 219 | A decline in cognitive function should lead to a change in disease-modifying therapy - Commentary. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1685-1686 | 5 | 2 |
| 218 | The dilemma of benign multiple sclerosis: Can we predict the risk of losing the "benign status"? A 12-year follow-up study. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 26, 71-73 | 4 | 5 |
| 217 | Author response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. <i>Neurology</i> , 2018 , 91, 851 | 6.5 | 2 |
| 216 | A case of Takotsubo syndrome during a multiple sclerosis brainstem relapse. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 24, 1-2 | 4 | 7 |
| 215 | Cognitive assessment in multiple sclerosis-an Italian consensus. <i>Neurological Sciences</i> , 2018 , 39, 1317-1334 | 3.5 | 18 |
| 214 | Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 266-276 | 5 | 22 |
| 213 | Effect of organizational features on patient satisfaction with care in Italian multiple sclerosis centres. <i>European Journal of Neurology</i> , 2017 , 24, 631-637 | 6 | 9 |
| 212 | Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 196-203 | 5.5 | 43 |
| 211 | The diagnostic dilemma of multiple sclerosis presenting with isolated cognitive and behavioral disorders. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1561-1563 | 5 | 1 |

| | | | |
|-----|--|------|-----|
| 210 | Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017 , 81, 729-739 | 9.4 | 26 |
| 209 | Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). <i>Journal of Neurology</i> , 2017 , 264, 2436-2449 | 5.5 | 35 |
| 208 | Clinical outcome measures for progressive MS trials. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1627-1635 | 5 | 27 |
| 207 | Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab. <i>CKJ: Clinical Kidney Journal</i> , 2017 , 10, 625-631 | 4.5 | 15 |
| 206 | MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients. <i>Neurology</i> , 2017 , 89, 1265-1273 | 6.5 | 9 |
| 205 | Maturation Trajectory of Processing Speed Performance in Pediatric Multiple Sclerosis. <i>Developmental Neuropsychology</i> , 2017 , 42, 299-308 | 1.8 | 3 |
| 204 | Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. <i>Neurological Sciences</i> , 2017 , 38, 1849-1858 | 3.5 | 19 |
| 203 | The still under-investigated role of cognitive deficits in PML diagnosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017 , 2, | 0 | 3 |
| 202 | Disease modifying treatments and symptomatic drugs for cognitive impairment in multiple sclerosis: where do we stand?. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017 , 2, | 0 | 6 |
| 201 | Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1258-1267 | 5 | 136 |
| 200 | Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017 , 140, 2426-2443 | 11.2 | 62 |
| 199 | Beyond Disease: Happiness, Goals, and Meanings among Persons with Multiple Sclerosis and Their Caregivers. <i>Frontiers in Psychology</i> , 2017 , 8, 2216 | 3.4 | 19 |
| 198 | Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability. <i>Frontiers in Neurology</i> , 2017 , 8, 608 | 4.1 | 12 |
| 197 | Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. <i>Journal of Clinical Psychology in Medical Settings</i> , 2016 , 23, 33-52 | 2 | 27 |
| 196 | Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 628-40 | 5 | 20 |
| 195 | Immunomodulatory therapies delay disease progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1732-1740 | 5 | 36 |
| 194 | The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 520-32 | 5 | 30 |
| 193 | Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 292-301 | 5 | 13 |

| | | | |
|-----|---|------|-----|
| 192 | Pediatric multiple sclerosis: Conventional first-line treatment and general management. <i>Neurology</i> , 2016 , 87, S97-S102 | 6.5 | 56 |
| 191 | International Pediatric MS Study Group Global Members Symposium report. <i>Neurology</i> , 2016 , 87, S110-66.5 | 6.5 | 16 |
| 190 | Pediatric multiple sclerosis: Cognition and mood. <i>Neurology</i> , 2016 , 87, S82-7 | 6.5 | 60 |
| 189 | Pediatric multiple sclerosis: Clinical features and outcome. <i>Neurology</i> , 2016 , 87, S74-81 | 6.5 | 80 |
| 188 | The heritage of glatiramer acetate and its use in multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016 , 1, | 0 | 8 |
| 187 | Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. <i>Annals of Neurology</i> , 2016 , 79, 288-94 | 9.4 | 96 |
| 186 | No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1163-73 | 5 | 18 |
| 185 | The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1741-1749 | 5 | 19 |
| 184 | A 10-year follow-up of the European multicenter trial of interferon β 1b in secondary-progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 533-43 | 5 | 18 |
| 183 | Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 93-9 | 5.5 | 125 |
| 182 | The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retrospective Study. <i>PLoS ONE</i> , 2016 , 11, e0157721 | 3.7 | 3 |
| 181 | Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016 , 139, 2395-405 | 11.2 | 172 |
| 180 | Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1343-1349 | 5.5 | 44 |
| 179 | Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 944-51 | 5.5 | 63 |
| 178 | History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort. <i>Neurology</i> , 2016 , 87, 1360-7 | 6.5 | 13 |
| 177 | Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 956-9 | 5 | 21 |
| 176 | Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound. <i>Brain, Behavior, and Immunity</i> , 2015 , 50, 78-86 | 16.6 | 37 |
| 175 | Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 479-91 | 5.3 | 36 |

| | | | |
|-----|--|------|-----|
| 174 | Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. <i>CNS Drugs</i> , 2015 , 29, 207-20 | 6.7 | 58 |
| 173 | Appraisal of brain connectivity in radiologically isolated syndrome by modeling imaging measures. <i>Journal of Neuroscience</i> , 2015 , 35, 550-8 | 6.6 | 30 |
| 172 | Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. <i>JAMA Neurology</i> , 2015 , 72, 405-13 | 17.2 | 83 |
| 171 | Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. <i>Brain</i> , 2015 , 138, 3275-86 | 11.2 | 63 |
| 170 | Long-term assessment of no evidence of disease activity in relapsing-remitting MS. <i>Neurology</i> , 2015 , 85, 1722-3 | 6.5 | 22 |
| 169 | Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1159-71 | 5 | 30 |
| 168 | A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. <i>BMC Neurology</i> , 2015 , 15, 204 | 3.1 | 28 |
| 167 | Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015 , 1, 2055217315600193 | 2.7 | 5 |
| 166 | A steroid-induced bilateral avascular necrosis of the femoral head in an underage patient affected by multiple sclerosis. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2015 , 12, 257-9 | | 8 |
| 165 | Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. <i>Neurology</i> , 2015 , 84, 981-8 | 6.5 | 155 |
| 164 | Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. <i>Lancet Neurology</i> , 2015 , 14, 302-17 | 24.1 | 322 |
| 163 | Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015 , 10, e0122686 | 3.7 | 80 |
| 162 | Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene. <i>PLoS ONE</i> , 2015 , 10, e0135441 | 3.7 | 3 |
| 161 | Guidelines on the clinical use for the detection of neutralizing antibodies (NABs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. <i>Neurological Sciences</i> , 2014 , 35, 307-16 | 3.5 | 28 |
| 160 | Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 739-46 | 5 | 104 |
| 159 | Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up. <i>Neurology</i> , 2014 , 83, 1432-8 | 6.5 | 78 |
| 158 | Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , 2014 , 76, 880-90 | 9.4 | 57 |
| 157 | Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 214-9 | 5 | 37 |

| | | | |
|-----|---|------|-----|
| 156 | Anxiety state affects information processing speed in patients with multiple sclerosis. <i>Neurological Sciences</i> , 2014 , 35, 559-63 | 3.5 | 39 |
| 155 | The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. <i>Journal of the Neurological Sciences</i> , 2014 , 337, 67-73 | 3.2 | 28 |
| 154 | Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. <i>BMC Neurology</i> , 2014 , 14, 114 | 3.1 | 22 |
| 153 | Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. <i>BMC Neurology</i> , 2014 , 14, 65 | 3.1 | 43 |
| 152 | Emotional and neutral verbal memory impairment in Multiple Sclerosis. <i>Journal of the Neurological Sciences</i> , 2014 , 341, 28-31 | 3.2 | 8 |
| 151 | Radiologically isolated syndrome: 5-year risk for an initial clinical event. <i>PLoS ONE</i> , 2014 , 9, e90509 | 3.7 | 190 |
| 150 | Assessing executive function with the D-KEFS sorting test: normative data for a sample of the Italian adult population. <i>Neurological Sciences</i> , 2014 , 35, 1895-902 | 3.5 | 15 |
| 149 | Intranetwork and internetwork functional connectivity abnormalities in pediatric multiple sclerosis. <i>Human Brain Mapping</i> , 2014 , 35, 4180-92 | 5.9 | 34 |
| 148 | Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 845-50 | 5.5 | 48 |
| 147 | The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. <i>BMC Neurology</i> , 2014 , 14, 171 | 3.1 | 78 |
| 146 | Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 91-8 | 5 | 81 |
| 145 | Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1511-22 | 5 | 49 |
| 144 | Posterior brain damage and cognitive impairment in pediatric multiple sclerosis. <i>Neurology</i> , 2014 , 82, 1314-21 | 6.5 | 40 |
| 143 | The RaoB Brief Repeatable Battery version B: normative values with age, education and gender corrections in an Italian population. <i>Neurological Sciences</i> , 2014 , 35, 79-82 | 3.5 | 22 |
| 142 | MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients. <i>PLoS ONE</i> , 2014 , 9, e94794 | 3.7 | 12 |
| 141 | Treatment of cognitive impairment in multiple sclerosis: position paper. <i>Journal of Neurology</i> , 2013 , 260, 1452-68 | 5.5 | 161 |
| 140 | Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient. <i>Journal of Neurology</i> , 2013 , 260, 1675-7 | 5.5 | 23 |
| 139 | Increased CD8+ T cell responses to apoptotic T cell-associated antigens in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2013 , 10, 94 | 10.1 | 20 |

| | | | |
|-----|--|------|-----|
| 138 | Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. <i>Expert Review of Clinical Immunology</i> , 2013 , 9, 683-91; quiz 692 | 5.1 | 15 |
| 137 | International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1261-7 | 5 | 646 |
| 136 | Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013 , 136, 3609-17 | 11.2 | 96 |
| 135 | Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation. <i>Clinical Neurology and Neurosurgery</i> , 2013 , 115, 1044-8 | 2 | 3 |
| 134 | Fluctuations of MS births and UV-light exposure. <i>Acta Neurologica Scandinavica</i> , 2013 , 127, 301-8 | 3.8 | 8 |
| 133 | Prevalence of patient-reported dysphagia in multiple sclerosis patients: an Italian multicenter study (using the DYMUS questionnaire). <i>Journal of the Neurological Sciences</i> , 2013 , 331, 94-7 | 3.2 | 39 |
| 132 | Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. <i>PLoS ONE</i> , 2013 , 8, e63480 | 3.7 | 22 |
| 131 | Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. <i>Neurological Sciences</i> , 2013 , 34, 1633-7 | 3.5 | 17 |
| 130 | Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. <i>Neurology</i> , 2013 , 80, 2090-4 | 6.5 | 51 |
| 129 | Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 961-3 | 5 | 14 |
| 128 | Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study. <i>Neurology</i> , 2013 , 80, 1728-33 | 6.5 | 93 |
| 127 | Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prospective, non-randomized pilot study. <i>European Journal of Neurology</i> , 2013 , 20, 986-90 | 6 | 39 |
| 126 | Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe. <i>Expert Review of Neurotherapeutics</i> , 2013 , 13, 61-6 | 4.3 | 3 |
| 125 | Subcutaneous interferon β 1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. <i>PLoS ONE</i> , 2013 , 8, e74111 | 3.7 | 42 |
| 124 | Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1636-9 | 5 | 44 |
| 123 | Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β 1a: results from the COGIMUS (COGNitive Impairment in MULTiple Sclerosis) study (II). <i>Quality of Life Research</i> , 2012 , 21, 1111-21 | 3.7 | 7 |
| 122 | Management options in multiple sclerosis-associated fatigue. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 207-16 | 4 | 38 |
| 121 | Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. <i>BMC Neurology</i> , 2012 , 12, 124 | 3.1 | 72 |

| | | | |
|-----|--|------|-----|
| 120 | Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. <i>BMC Neurology</i> , 2012 , 12, 165 | 3.1 | 66 |
| 119 | Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. <i>BMC Neurology</i> , 2012 , 12, 55 | 3.1 | 208 |
| 118 | Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 116-27 | 5 | 149 |
| 117 | Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. <i>PLoS ONE</i> , 2012 , 7, e35843 | 3.7 | 68 |
| 116 | Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 835-42 | 5 | 95 |
| 115 | A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 825-34 | 5 | 70 |
| 114 | No association between chronic cerebrospinal venous insufficiency and pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1791-6 | 5 | 18 |
| 113 | Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 329-34 | 5 | 65 |
| 112 | Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. <i>Neurology</i> , 2012 , 78, 309-14 | 6.5 | 129 |
| 111 | Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). <i>Multiple Sclerosis Journal</i> , 2012 , 18, 891-8 | 5 | 493 |
| 110 | Truly benign multiple sclerosis is rare: let's stop fooling ourselves--yes. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 13-4 | 5 | 18 |
| 109 | Relevance of brain lesion location to cognition in relapsing multiple sclerosis. <i>PLoS ONE</i> , 2012 , 7, e44826 | 3.7 | 61 |
| 108 | Geographical variations in sex ratio trends over time in multiple sclerosis. <i>PLoS ONE</i> , 2012 , 7, e48078 | 3.7 | 139 |
| 107 | Supportive strategies to improve adherence to IFN β 1b in multiple sclerosis--results of the Plus observational cohort study. <i>Journal of the Neurological Sciences</i> , 2011 , 307, 120-6 | 3.2 | 54 |
| 106 | Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. <i>Lancet Neurology</i> , 2011 , 10, 520-9 | 24.1 | 178 |
| 105 | Three years of experience: the Italian registry and safety data update. <i>Neurological Sciences</i> , 2011 , 31 Suppl 3, 295-7 | 3.5 | 25 |
| 104 | Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society. <i>Neurological Sciences</i> , 2011 , 32, 351-8 | 3.5 | 15 |
| 103 | Multiple sclerosis in Italy: cost-of-illness study. <i>Neurological Sciences</i> , 2011 , 32, 787-94 | 3.5 | 29 |

| | | | |
|-----|---|-----|-----|
| 102 | The direct cost of patients with multiple sclerosis: a survey from Italian MS centres. <i>Neurological Sciences</i> , 2011 , 32, 1035-41 | 3.5 | 20 |
| 101 | Cognitive impairment and event-related potentials in paediatric multiple sclerosis: 2-year study. <i>Neurological Sciences</i> , 2011 , 32, 1043-6 | 3.5 | 11 |
| 100 | Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. <i>Neurological Sciences</i> , 2011 , 32, 1223-31 | 3.5 | 33 |
| 99 | Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β 1a in the COGNITIVE Impairment in Multiple Sclerosis (COGIMUS) study. <i>BMC Neurology</i> , 2011 , 11, 125 | 3.1 | 11 |
| 98 | Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. <i>Journal of Translational Medicine</i> , 2011 , 9, 42 | 8.5 | 9 |
| 97 | Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 1355-9 | 5.5 | 17 |
| 96 | Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. <i>Neurology</i> , 2011 , 77, 1887-95 | 6.5 | 59 |
| 95 | Is there a future for donepezil therapy in the treatment of multiple sclerosis-related cognitive impairment?. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 1243-6 | 4.3 | 4 |
| 94 | Cortical lesions in radiologically isolated syndrome. <i>Neurology</i> , 2011 , 77, 1896-9 | 6.5 | 67 |
| 93 | Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGNITIVE Impairment in Multiple Sclerosis) study. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 991-1001 | 5 | 39 |
| 92 | Breastfeeding is not related to postpartum relapses in multiple sclerosis. <i>Neurology</i> , 2011 , 77, 145-50 | 6.5 | 116 |
| 91 | Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis. <i>PLoS ONE</i> , 2011 , 6, e19452 | 3.7 | 55 |
| 90 | Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population. <i>PLoS ONE</i> , 2010 , 5, e9287 | 3.7 | 51 |
| 89 | Cognitive and Psychiatric Disorders in Multiple Sclerosis. <i>Blue Books of Neurology</i> , 2010 , 147-158 | | |
| 88 | Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 62-7 | 5 | 118 |
| 87 | Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. <i>Neurology</i> , 2010 , 75, 1134-40 | 6.5 | 170 |
| 86 | Cortical functional reorganization and its relationship with brain structural damage in patients with benign multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1326-34 | 5 | 24 |
| 85 | Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1474-82 | 5 | 136 |

| | | | |
|----|---|-----|-----|
| 84 | Reliability, practice effects, and change indices for RaoB Brief Repeatable Battery. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 611-7 | 5 | 43 |
| 83 | Pregnancy and fetal outcomes after interferon- β exposure in multiple sclerosis. <i>Neurology</i> , 2010 , 75, 1794-802 | 6.5 | 121 |
| 82 | Evolving expectations around early management of multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2010 , 3, 351-67 | 6.6 | 74 |
| 81 | The management of multiple sclerosis in children: a European view. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1258-67 | 5 | 69 |
| 80 | Impact of cognitive impairment on coping strategies in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2010 , 112, 127-30 | 2 | 40 |
| 79 | Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 68-77 | 5 | 75 |
| 78 | Psychosocial issue in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , 2010 , 31, 467-70 | 3.5 | 36 |
| 77 | Coping strategies, cognitive impairment, psychological variables and their relationship with quality of life in multiple sclerosis. <i>Neurological Sciences</i> , 2010 , 31, S227-30 | 3.5 | 69 |
| 76 | Cognitive impairment in early stages of multiple sclerosis. <i>Neurological Sciences</i> , 2010 , 31, S211-4 | 3.5 | 113 |
| 75 | Cognitive rehabilitation in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , 2010 , 31, S275-8 | 3.5 | 13 |
| 74 | Cognitive impairment in pediatric multiple sclerosis. <i>Neurological Sciences</i> , 2010 , 31, S215-8 | 3.5 | 20 |
| 73 | The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 620-6 | 5 | 44 |
| 72 | Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 779-88 | 5 | 141 |
| 71 | Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients. <i>European Neurology</i> , 2009 , 61, 177-82 | 2.1 | 11 |
| 70 | Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study. <i>Therapeutic Advances in Neurological Disorders</i> , 2009 , 2, 67-77 | 6.6 | 10 |
| 69 | Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. <i>Neurology</i> , 2009 , 73, 498-503 | 6.5 | 74 |
| 68 | Cognitive and psychosocial features of childhood and juvenile MS. <i>Neurology</i> , 2009 , 72, 1189; author reply 1189-90 | 6.5 | 3 |
| 67 | A short version of RaoB Brief Repeatable Battery as a screening tool for cognitive impairment in multiple sclerosis. <i>Clinical Neuropsychologist</i> , 2009 , 23, 268-75 | 4.4 | 31 |

| | | | |
|----|--|-----|-----|
| 66 | APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 1489-94 | 5 | 17 |
| 65 | The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 472-8 | 5 | 26 |
| 64 | Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 403; author reply 404 | 5 | 2 |
| 63 | Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2009 , 66, 513-20 | 9.4 | 109 |
| 62 | Coping strategies, psychological variables and their relationship with quality of life in multiple sclerosis. <i>Neurological Sciences</i> , 2009 , 30, 15-20 | 3.5 | 88 |
| 61 | Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. <i>Neurological Sciences</i> , 2009 , 30, 193-9 | 3.5 | 58 |
| 60 | The pharmacovigilance program on natalizumab in Italy: 2 years of experience. <i>Neurological Sciences</i> , 2009 , 30 Suppl 2, S163-5 | 3.5 | 14 |
| 59 | Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. <i>Journal of Neurology</i> , 2009 , 256, 1891-8 | 5.5 | 101 |
| 58 | ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2009 , 120, 439-41 | 3.8 | 8 |
| 57 | Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. <i>Journal of the Neurological Sciences</i> , 2009 , 284, 223; author reply 223-4 | 3.2 | 4 |
| 56 | Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. <i>Journal of the Neurological Sciences</i> , 2009 , 286, 109-13 | 3.2 | 22 |
| 55 | Improving compliance with interferon-beta therapy in patients with multiple sclerosis. <i>CNS Drugs</i> , 2009 , 23, 453-62 | 6.7 | 30 |
| 54 | Subclinical MSP follow-up of four cases. <i>European Journal of Neurology</i> , 2008 , 15, 858-61 | 6 | 28 |
| 53 | Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment. <i>Journal of Neuroimmunology</i> , 2008 , 199, 142-50 | 3.5 | 69 |
| 52 | Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. <i>Journal of the Neurological Sciences</i> , 2008 , 266, 25-30 | 3.2 | 22 |
| 51 | Cognitive changes in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2008 , 8, 1585-96 | 4.3 | 119 |
| 50 | Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. <i>Neurology</i> , 2008 , 71, 632-8 | 6.5 | 95 |
| 49 | Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. <i>European Neurology</i> , 2008 , 59, 131-5 | 2.1 | 78 |

| | | | |
|----|--|------|-----|
| 48 | Cognitive and psychosocial features of childhood and juvenile MS. <i>Neurology</i> , 2008 , 70, 1891-7 | 6.5 | 209 |
| 47 | Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 1225-33 | 5 | 58 |
| 46 | Natalizumab: a country-based surveillance program. <i>Neurological Sciences</i> , 2008 , 29 Suppl 2, S235-7 | 3.5 | 9 |
| 45 | Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2008 , 63, 126; author reply 126-7 | 9.4 | 1 |
| 44 | Clinical outcome measures in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2007 , 259, 118-22 | 3.2 | 42 |
| 43 | New natural history of interferon-beta-treated relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2007 , 61, 300-6 | 9.4 | 208 |
| 42 | Motor evoked potentials in multiple sclerosis patients without walking limitation: amplitude vs. conduction time abnormalities. <i>Journal of Neurology</i> , 2007 , 254, 220-7 | 5.5 | 24 |
| 41 | Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. <i>Neurological Sciences</i> , 2007 , 28, 127-32 | 3.5 | 49 |
| 40 | Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 757-9 | 5.5 | 47 |
| 39 | Caregiver quality of life in multiple sclerosis: a multicentre Italian study. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 412-9 | 5 | 68 |
| 38 | Longitudinal follow-up of "benign" multiple sclerosis at 20 years. <i>Neurology</i> , 2007 , 69, 938; author reply 938-9 | 6.5 | 4 |
| 37 | Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. <i>Archives of Neurology</i> , 2007 , 64, 1157-61 | | 174 |
| 36 | Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 676-8 | 5 | 24 |
| 35 | Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. <i>Brain</i> , 2006 , 129, 2008-16 | 11.2 | 68 |
| 34 | The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 578-85 | 5 | 26 |
| 33 | The RaoB Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 787-93 | 5 | 273 |
| 32 | Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 281-6 | 5 | 29 |
| 31 | Are there protective treatments for cognitive decline in MS?. <i>Journal of the Neurological Sciences</i> , 2006 , 245, 183-6 | 3.2 | 41 |

| | | | |
|----|---|------|-----|
| 30 | Neocortical volume decrease in relapsing-remitting multiple sclerosis with mild cognitive impairment. <i>Journal of the Neurological Sciences</i> , 2006 , 245, 195-9 | 3.2 | 28 |
| 29 | Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. <i>Journal of the Neurological Sciences</i> , 2006 , 245, 41-6 | 3.2 | 404 |
| 28 | Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta. <i>Journal of the Neurological Sciences</i> , 2006 , 244, 97-102 | 3.2 | 30 |
| 27 | Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. <i>Journal of Neurology</i> , 2006 , 253, 1054-9 | 5.5 | 123 |
| 26 | Donepezil for memory impairment in multiple sclerosis. <i>Lancet Neurology</i> , 2005 , 4, 72-3 | 24.1 | 12 |
| 25 | Clinical correlations of CSF single IgG bands. <i>Journal of Neurology</i> , 2005 , 252, 1274-5 | 5.5 | 9 |
| 24 | Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study. <i>Neurological Sciences</i> , 2005 , 26 Suppl 4, S183-6 | 3.5 | 52 |
| 23 | Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 420-4 | 5 | 90 |
| 22 | Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. <i>Neurology</i> , 2004 , 63, 89-93 | 6.5 | 253 |
| 21 | Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 2115-26 | 4 | 11 |
| 20 | The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. <i>Neurology</i> , 2004 , 63, 919-21 | 6.5 | 221 |
| 19 | Altered cerebellar functional connectivity mediates potential adaptive plasticity in patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004 , 75, 840-6 | 5.5 | 60 |
| 18 | European validation of a standardized clinical description of multiple sclerosis. <i>Journal of Neurology</i> , 2004 , 251, 1472-80 | 5.5 | 35 |
| 17 | Cerebrospinal fluid findings in Devic's neuromyelitis optica. <i>Neurological Sciences</i> , 2004 , 25 Suppl 4, S368-70 | 5.5 | 30 |
| 16 | Italian studies on early-onset multiple sclerosis: the present and the future. <i>Neurological Sciences</i> , 2004 , 25 Suppl 4, S346-9 | 3.5 | 17 |
| 15 | A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. <i>Journal of the Neurological Sciences</i> , 2004 , 223, 69-71 | 3.2 | 23 |
| 14 | Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. <i>Archives of Neurology</i> , 2004 , 61, 536-40 | | 42 |
| 13 | Changes in neuropsychological test performance over the workday in multiple sclerosis. <i>Clinical Neuropsychologist</i> , 2003 , 17, 551-60 | 4.4 | 32 |

| | | | |
|----|---|------|-----|
| 12 | Interobserver agreement on Poser ^B and the new McDonald ^B diagnostic criteria for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 481-5 | 5 | 15 |
| 11 | Safety and tolerability of cyclophosphamide pulses ^P in multiple sclerosis: a prospective study in a clinical cohort. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 446-50 | 5 | 28 |
| 10 | Can the Expanded Disability Status Scale be assessed by telephone?. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 154-9 | 5 | 103 |
| 9 | The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. <i>Journal of Neurology</i> , 2002 , 249, 152-63 | 5.5 | 74 |
| 8 | Cognitive dysfunction in multiple sclerosis: current approaches to clinical management. <i>Expert Review of Neurotherapeutics</i> , 2002 , 2, 731-42 | 4.3 | 1 |
| 7 | Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. <i>Archives of Neurology</i> , 2001 , 58, 1602-6 | | 489 |
| 6 | A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. <i>Journal of the Neurological Sciences</i> , 1999 , 168, 96-106 | 3.2 | 98 |
| 5 | Quantification of impairment in MS: discussion of the scales in use. <i>Multiple Sclerosis Journal</i> , 1999 , 5, 216-9 | 5 | 46 |
| 4 | Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. <i>Archives of Neurology</i> , 1995 , 52, 168-72 | | 284 |
| 3 | The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients. <i>Journal of Autoimmunity</i> , 1990 , 3, 587-92 | 15.5 | 14 |
| 2 | Cognitive dysfunction in pediatric-onset multiple sclerosis ¹³⁴⁻¹⁴³ | | 2 |
| 1 | Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. <i>Journal of Neurology</i> , | 5.5 | 2 |